Skin barrier and cutaneous targets

The skin barrier and cutaneous targets represent a broad category of molecular entities rather than a single receptor or enzyme. This group includes structural proteins such as Filaggrin (FLG) and Loricrin, which are essential for the formation of the cornified envelope, as well as tight junction proteins like Claudins that regulate paracellular permeability (Source: PubMed, PMID: 24638018). Additionally, cutaneous targets encompass various signaling molecules and receptors involved in skin immunity and homeostasis, such as Interleukin-4 receptor alpha (IL-4Rα) and Janus kinases (JAKs), which are central to the pathogenesis of inflammatory conditions like atopic dermatitis and psoriasis (Source: NIH, StatPearls). Pharmacological strategies targeting the skin barrier aim to either physically restore the lipid matrix or biochemically modulate the pathways that lead to barrier degradation. For instance, biologics like Dupilumab inhibit Th2-mediated inflammation that compromises barrier integrity, while topical retinoids influence keratinocyte differentiation (Source: FDA, Drug Labels). Because this term refers to a collection of diverse physiological components—including the stratum corneum, antimicrobial peptides, and various epidermal enzymes—it is classified as a therapeutic category rather than a specific canonical target. Understanding these targets is vital for developing precision therapies that address both the structural and immunological aspects of dermatological diseases.

Other names

Epidermal barrier componentsCutaneous drug targetsSkin barrier proteinsDermatological targets

Restoration of the cornified envelope, modulation of cytokine signaling (e.g., IL-4/IL-13 inhibition), regulation of keratinocyte proliferation, and replenishment of essential barrier lipids.